Jason M. Broderick

The 100% response rate for the combination was achieved in older patients with locally advanced or metastatic head and neck squamous cell carcinoma.

Dostarlimab previously received breakthrough therapy designation from the FDA for dMMR/MSI-H rectal cancer.

This is the third complete response letter the FDA has issued for rivoceranib plus camrelizumab for hepatocellular carcinoma.

The results jeopardize the accelerated approval of adagrasib plus cetuximab for KRAS G12C–mutated mCRC.

Building on these data, the ongoing phase 3 BATTMAN trial is exploring botensilimab plus balstilimab in refractory MSS mCRC.

The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.

The zoldonrasib data build on the recent historical breakthrough with daraxonrasib in PDAC.

It was previously shown that the STELLAR-303 trial achieved the coprimary end point of OS in the ITT population.

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

A phase 3 trial of givastomig is expected to begin as early as the fourth quarter of 2026.

The FDA concurrently cleared the VENTANA PTEN (SP218) RxDx assay as a companion diagnostic to identify eligible patients.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

"Sacituzumab govitecan plus pembrolizumab [led to] improvement in PFS2...despite the crossover design of the trial," said Eleonora Teplinsky, MD.

A review of top ASCO abstracts with the potential to change everyday oncology practice.

"This is one of very few studies in advanced squamous NSCLC that has shown median survival beyond 2 years," said Shun Lu, MD, PhD.

"Dedifferentiated liposarcoma is usually treated with surgery, but when it comes back, it is difficult to treat and often incurable," said Mark Dickson, MD.

"These findings may be considered practice changing for medical oncologists treating HCC globally,” said Vishwanath Sathyanarayanan, MD.

"Early molecular testing is critically important now in these [patients with] mCSPC,” said TALAPRO-3 lead investigator Neeraj Agarwal, MD, FASCO.

"I think the [PROTEUS] study will change the standard of care for many patients who are candidates for surgery and have high-risk localized prostate cancer,” said William K. Oh, MD.

“The results support daraxonrasib as the new standard of care for patients with previously treated metastatic PDAC,” said Brian Wolpin, MD.

"Adjuvant selpercatinib should be considered as a new standard of care in early-stage RET fusion–positive lung cancer,” said Jonathan Goldman, MD.

“This study is important in that it represents a potential therapy option for patients in resource-limited parts of the world," said Glenn J. Hanna, MD.

“MajesTEC-9 is the second phase 3 study to show a significant PFS and OS benefit in the second-line setting and beyond with teclistamab-based therapy for RRMM,” said Roberto Mina, MD.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

The phase 3 POTOMAC study was the supporting trial for the FDA approval of the durvalumab combination for BCG-naive NMIBC.